InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.86
(
-0.06%
)
Bitcoin
60,250.42
(
0.15%
)
Post# of 252477
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 152846

Wednesday, 11/21/2012 3:31:13 PM

Wednesday, November 21, 2012 3:31:13 PM

Post# of 252477
Yes, that’s the 21-patient Servier trial I was referring to—your link quotes 1/5/13 as the “end date,” so data will presumably be available in early 2013.

Inasmuch as this is an open-label trial and Servier recently agreed to an upgrade of the Servier/XOMA phase-3 program in uveitis, it’s reasonable to surmise that the results in the 21-patient trial will be reasonably strong.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up